Inclusion Criteria:

          1. Age > 55 years or

          2. Age < 55 and LVEF < 45% or creatinine clearance < 60 ml/min

          3. Ability to cover the cost of the transplant, necessary medications, and
             transportation/housing.

          4. Caregiver must be available while outpatient

        Guidelines for Cladribine-Melphalan-based conditioning:

          -  Bone Marrow Failure States Severe Aplastic Anemia (relapsed following
             immunosuppressive therapy) Paroxysmal Nocturnal Hemoglobinuria (poor prognostic
             features or hemosiderosis)

          -  AML (first CR except for t(15;17), inv16, t(8,21); second CR; relapse failing second
             induction attempt)

          -  ALL (first CR with at least one poor prognostic feature; second or greater CR; relapse
             failing reinduction attempt)

          -  MDS (RAEB, RAEBiT, CMMoL)

          -  CML (chronic phase; accelerated phase; blast phase following reinduction attempt; 2nd
             chronic or accelerated phase following gleevec therapy

          -  Hodgkin's lymphoma (first or greater relapse)

          -  Non-Hodgkin's Lymphoma

          -  Aggressive Histology (includes T Cell NHL) Incomplete response to induction Second CR
             Sensitive or refractory relapse

          -  Indolent Histology Second or greater relapse

          -  Mantle Cell Lymphoma (any Stage - must have received induction chemotherapy)

          -  Multiple Myeloma (10% residual plasmacytosis following anthracycline-based
             chemotherapy or residual disease following autologous transplant)

          -  Waldenstrom Macroglobulinemia (must have failed either purine analogue-based
             chemotherapy (Fludara or 2CdA) or standard CVP therapy; hyperviscosity or cytopenias)

        Guidelines for total lymphoid irradiation-based conditioning

          -  MDS (RA, RARS)

          -  CLL (Rai stage III or IV - must have received at least two different treatment
             regimens in the past)

          -  Breast Cancer (symptomatic metastatic disease, who have failed standard chemotherapy)

          -  Renal Cell Cancer (metastatic disease at multiple sites)

          -  Malignant Melanoma (metastatic disease at multiple sites)

          -  Sarcoma (all subtypes presently, unresectable metastatic disease)

          -  Ovarian Cancer (stage III or IV, platinum insensitive disease, i.e. progression within
             6 months of initial platinum chemotherapy)

          -  Thymoma (unresectable disease)

        Exclusion Criteria:

          1. Prior allogeneic stem cell or bone marrow transplant

          2. Current or past history of invasive mycotic infection

          3. Breast Feeding